Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1 Adjuvant Against Fluzone Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age

Trial Profile

A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1 Adjuvant Against Fluzone Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 11 Apr 2023 The protocol has been amended as above- 1) New primary endpoint has been added -Mean Difference in the Seroconversion Rate (SCR) HAI Antibody Responses. Time frames of adverse events has been differentiated.2)status has been completed.
  • 11 Apr 2023 Status changed from active, no longer recruiting to completed.
  • 20 Apr 2022 According to a Novavax media release, data were presented at the World Vaccine Congress (WVC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top